Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review

Mucenic, Marcos; Brandão, Ajácio Bandeira de Mello; Marroni, Cláudio Augusto; Fleck, Alfeu de Medeiros; Zanotelli, Maria Lúcia; Leipnitz, Ian; Meine, Mario Henrique Mendes de Mattos; Kiss, Guillermo; Martini, Juliano; Schlindwein, Eduardo; Costabeber, Ane Micheli; Sacco, Fernanda Karlinsky Rodrigues; Rossato, Giovana; Cantisani, Guido Pio Cracco

doi:10.1590/s1678-9946201961012

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ribavirin discovered in the 1970s is one of the most remarkable nucleoside antivirals due to its antiviral activities, both in tissue culture and animal models against a uniquely broad range of viruses including DNA and RNA viruses [ 17 ] ( Figure 4 ). Ribavirin [ 18 ] is an approved drug against hepatitis C infection in combination with interferons alpha or in combination with other medications such as sofosbuvir [ 54 , 55 ]. Ribavirin has also been used for the treatment of other viral infections [ 56 , 57 ].…”

Section: Broad-spectrum Antiviral Nucleoside Analoguesmentioning

confidence: 99%

Broad-Spectrum Antiviral Strategies and Nucleoside Analogues

Geraghty

Aliota

Bonnac

2021

Viruses

123

View full text Add to dashboard Cite

The emergence or re-emergence of viruses with epidemic and/or pandemic potential, such as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 1 and 2 (SARS and SARS-CoV-2) viruses, or new strains of influenza represents significant human health threats due to the absence of available treatments. Vaccines represent a key answer to control these viruses. However, in the case of a public health emergency, vaccine development, safety, and partial efficacy concerns may hinder their prompt deployment. Thus, developing broad-spectrum antiviral molecules for a fast response is essential to face an outbreak crisis as well as for bioweapon countermeasures. So far, broad-spectrum antivirals include two main categories: the family of drugs targeting the host-cell machinery essential for virus infection and replication, and the family of drugs directly targeting viruses. Among the molecules directly targeting viruses, nucleoside analogues form an essential class of broad-spectrum antiviral drugs. In this review, we will discuss the interest for broad-spectrum antiviral strategies and their limitations, with an emphasis on virus-targeted, broad-spectrum, antiviral nucleoside analogues and their mechanisms of action.

show abstract

Section: Broad-spectrum Antiviral Nucleoside Analoguesmentioning

confidence: 99%

Broad-Spectrum Antiviral Strategies and Nucleoside Analogues

Geraghty

Aliota

Bonnac

2021

Viruses

123

View full text Add to dashboard Cite

show abstract

“…For instance, telaprevir (an inhibitor of the HCV NS3/4 protease) in combination with PegIFN-␣/ribavirin can be effective in treating chronic HCV patients who are unresponsive to conventional PegIFN-␣/ribavirin therapy (55). Several other HCV NS3/4A protease inhibitors used in combination with PegIFN-␣ and ribavirin may also achieve improved rates of a sustained virological response (56)(57)(58)(59). However, the toxicity when they are combined with PegIFN-␣ and ribavirin still limits their overall efficacy (60,61).…”

Section: Fda-approved Host-directed Antiviral Agentsmentioning

confidence: 99%

Host-Directed Antiviral Therapy

et al. 2020

View full text Add to dashboard Cite

SUMMARY Antiviral drugs have traditionally been developed by directly targeting essential viral components. However, this strategy often fails due to the rapid generation of drug-resistant viruses. Recent genome-wide approaches, such as those employing small interfering RNA (siRNA) or clustered regularly interspaced short palindromic repeats (CRISPR) or those using small molecule chemical inhibitors targeting the cellular “kinome,” have been used successfully to identify cellular factors that can support virus replication. Since some of these cellular factors are critical for virus replication, but are dispensable for the host, they can serve as novel targets for antiviral drug development. In addition, potentiation of immune responses, regulation of cytokine storms, and modulation of epigenetic changes upon virus infections are also feasible approaches to control infections. Because it is less likely that viruses will mutate to replace missing cellular functions, the chance of generating drug-resistant mutants with host-targeted inhibitor approaches is minimized. However, drug resistance against some host-directed agents can, in fact, occur under certain circumstances, such as long-term selection pressure of a host-directed antiviral agent that can allow the virus the opportunity to adapt to use an alternate host factor or to alter its affinity toward the target that confers resistance. This review describes novel approaches for antiviral drug development with a focus on host-directed therapies and the potential mechanisms that may account for the acquisition of antiviral drug resistance against host-directed agents.

show abstract

Peginterferon/ribavirin

2019

Reactions Weekly

View full text Add to dashboard Cite

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review

Cited by 4 publications

References 21 publications

Broad-Spectrum Antiviral Strategies and Nucleoside Analogues

Broad-Spectrum Antiviral Strategies and Nucleoside Analogues

Host-Directed Antiviral Therapy

Peginterferon/ribavirin

Contact Info

Product

Resources

About